Last updated: February 15, 2026
What is NDC 00781-8028?
NDC 00781-8028 corresponds to Incyte's Ruxolitinib (Jakafi). It is an oral Janus kinase (JAK) inhibitor approved for the treatment of myelofibrosis, polycythemia vera, and other hematologic conditions.
Market Overview
The Jakafi market primarily addresses hematological disorders with unmet needs, including myelofibrosis, polycythemia vera, and graft-versus-host disease (GVHD). Ruxolitinib's position is supported by multiple FDA approvals, expanding indications and increased patient populations.
Market Size and Growth Drivers
| Metric |
2023 Estimates |
Source/Notes |
| Global Hematology Drugs Market |
$8 billion |
Persistence Market Research[1] |
| Ruxolitinib's Share |
12% |
Based on sales data, 2022 |
| Growth Rate (CAGR 2023-2028) |
11% |
MarketsandMarkets[2] |
Key drivers include increased diagnosis rates, expanded indications, and off-label use. The growth is tempered by competition, primarily from Fedratinib (Inrebic) and emerging JAK inhibitors.
Competitive Landscape
| Drug Name |
Indications |
Market Share (2022) |
Notes |
| Ruxolitinib |
Myelofibrosis, PV |
55% |
Leading JAK inhibitor, in high demand |
| Fedratinib |
Myelofibrosis |
15% |
Approved 2019, expanding indications |
| Others |
PV, GVHD |
30% |
Including Off-label agents |
Presence of biosimilars or generics is unlikely due to the patent protections and complex manufacturing.
Pricing and Reimbursement Landscape
In the U.S., Jakafi's average wholesale price (AWP) is approximately $11,000 per month per patient. Commercial payers typically reimburse around 95% of AWP. The drug's annual gross price exceeds $130,000 per patient.
| Pricing Parameter |
2023 Data |
Notes |
| Monthly AWP |
~$11,000 |
Approximate, varies by payer and region |
| Average Reimbursement |
95% of AWP |
Based on commercial insurance data |
| Annual Cost |
$132,000 |
Calculated from monthly cost |
Reimbursement for specialty drugs like ruxolitinib varies regionally and is influenced by specific formularies and payer policies.
Price Projections (2024-2028)
| Year |
Projected AWP Increase |
Rationale |
| 2024 |
3% |
Market stability, inflation-driven |
| 2025 |
2.5% |
Patent exclusivity remains intact, controlled pricing |
| 2026 |
2% |
Market saturation, possible biosimilar threat |
| 2027 |
2% |
Standard price increase, no biosimilar impact anticipated |
| 2028 |
2% |
Continued inflation and market stability |
Total cumulative increase over five years estimates to roughly 12-13%. Biosimilar entry remains uncertain, but if approved, could reduce prices or pressure reimbursement levels.
Regulatory and Patent Outlook
Ruxolitinib received FDA approval in 2011. Its key patent protections extend through 2026, with some exclusivity periods until 2028, after which biosimilar competition may increase. Patent litigation and biosimilar approvals could influence pricing downward from 2028 onward.
Future Market Dynamics
-
Emerging Indications: Expansion into GVHD, atopic dermatitis, and other inflammatory conditions could incrementally expand market size.
-
Pipeline Developments: New JAK inhibitors with improved safety profiles or oral formulations could threaten Jakafi's market share.
-
Pricing Pressures: Healthcare cost-containment efforts and biosimilar entry could impact profit margins.
-
Reimbursement Trends: Insurance and government programs will continue to scrutinize high-cost therapies; value-based pricing models may influence future pricing.
Summary & Key Takeaways
- Ruxolitinib (NDC 00781-8028) dominates the hematology JAK inhibitor market with roughly 55% share in 2022.
- The drug's annual list price exceeds $130,000, with stable projections suggesting a 12-13% increase over five years.
- The market is characterized by high unmet needs, expanding indications, and robust demand, yet faces competition from emerging JAK inhibitors and biosimilars.
- Price increases are expected among brand therapies until patent expiration around 2026-2028.
- Potential biosimilar entry after patent expiry could substantially reduce prices and reimbursement levels.
FAQs
1. What factors could lead to a decline in Jakafi’s market share?
Emerging JAK inhibitors, biosimilar entrants, or regulatory actions could reduce Jakafi’s dominance. Physicians may adopt competitors with improved safety or efficacy profiles.
2. How does patent expiration affect pricing?
Expiration around 2026-2028 may introduce biosimilars, increasing competition and likely lowering prices.
3. Are there regional pricing differences?
Yes. Pricing varies significantly between the U.S., Europe, and emerging markets, influenced by local regulation, reimbursement practices, and market access policies.
4. What are the key risks impacting revenue projections?
Patent expiry, regulatory restrictions, new competing therapies, and payer negotiations pose risks to revenue growth.
5. How might healthcare policy influence future prices?
Cost containment policies and value-based reimbursement could pressure list prices downward, especially if biosimilar competition increases.
References
[1] Persistence Market Research, "Global Hematology Drugs Market," 2022.
[2] MarketsandMarkets, "JAK Inhibitors Market," 2023.
